New Research on 2 Million People shows the 28 Benefits and 16 Risks of Ozempic and Wegovy

In this episode we look at the extensive research on the benefits and risks of GLP-1s based on a study of almost 2 million patients. A groundbreaking study published in the respected science journal Nature. The research explored how GLP-1 receptor agonists (like Ozempic and Wegovy) impact 175 health conditions. Total Participants: 1,955,135 individuals Follow-up Period: Median of 3.68 years (range: 2.05-5.37 years) Total Study Duration: 7,239,854 person-years Key Objective: Systematically examine associations between GLP-1 receptor agonist use and 175 health outcomes Picture this: a team of dedicated researchers tracking nearly two million people over several years. To put this into perspective, most medical studies might include a few thousand participants. This study represents the gold standard: large-scale, long-term and rigorously documented. The results show that GLP-1 medications can help with many health problems, from heart disease to mental health. However, the study also points out some risks, especially with gastrointestinal issues and kidney health. Though there are still risks to consider, this research shows how far we’ve come in understanding and improving health. We still have challenges to face, but it highlights how much we can achieve when we truly understand our bodies. Read our companion blog post on this episode